Associated Genetic Biomarkers
DOT1L Mutation is present in 1.83% of AACR GENIE cases, with lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, breast invasive ductal carcinoma, and prostate adenocarcinoma having the greatest prevalence .
DOT1L Mutation serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains DOT1L Mutation as an inclusion criterion, 1 is phase 2 (1 open).
Trials with DOT1L Mutation in the inclusion eligibility criteria most commonly target bladder carcinoma and urothelial carcinoma .
Olaparib is the most frequent therapy in trials with DOT1L Mutation as an inclusion criteria .
Significance of DOT1L Mutation in Diseases
Urothelial Carcinoma +
DOT1L is altered in 3.66% of urothelial carcinoma patients with DOT1L Mutation present in 3.66% of all urothelial carcinoma patients .
DOT1L Mutation is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DOT1L Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
Bladder Carcinoma +
DOT1L is altered in 2.98% of bladder carcinoma patients with DOT1L Mutation present in 2.98% of all bladder carcinoma patients .
DOT1L Mutation is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DOT1L Mutation and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.